 | • レポートコード：MRC2303G040 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療機器 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の心臓マッピング市場規模が、予測期間（2023年-2028年）中、CAGR 8.5％で増加すると推測されています。本書では、心臓マッピングの世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（接触型、非接触型）分析、疾患別（心房細動、心房粗動、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Abbott Laboratories、Acutus Medical、Angiodynamics、APN Health, LLC、Biosense Webster, Inc.などが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の心臓マッピング市場規模：種類別 - 接触型心臓マッピングシステムの市場規模 - 非接触型心臓マッピングシステムの市場規模 ・世界の心臓マッピング市場規模：疾患別 - 心房細動における市場規模 - 心房粗動における市場規模 - その他疾患における市場規模 ・世界の心臓マッピング市場規模：地域別 - 北米の心臓マッピング市場規模 アメリカの心臓マッピング市場規模 カナダの心臓マッピング市場規模 メキシコの心臓マッピング市場規模 … - ヨーロッパの心臓マッピング市場規模 ドイツの心臓マッピング市場規模 イギリスの心臓マッピング市場規模 フランスの心臓マッピング市場規模 … - アジア太平洋の心臓マッピング市場規模 中国の心臓マッピング市場規模 日本の心臓マッピング市場規模 インドの心臓マッピング市場規模 … - 南米/中東の心臓マッピング市場規模 ブラジルの心臓マッピング市場規模 アルゼンチンの心臓マッピング市場規模 サウジアラビアの心臓マッピング市場規模 ・競争状況 ・市場機会・将来動向 |
The cardiac mapping market is projected to register a CAGR of 8.5% during the forecast period (2023 – 2028).
The COVID-19 pandemic harmed the cardiac mapping market. Various research studies have been published to provide insight into the impact of the pandemic on the market. For instance, a research study published titled “Cardiac Involvement of COVID-19: A Comprehensive Review” published in January 2021 stated that COVID-19 can significantly affect patients’ cardiovascular systems. Mortality from COVID-19 is strongly associated with cardiovascular disease, diabetes, and hypertension. Hence, patients suffering from Cardiovascular diseases must take more precautions against COVID-19, which may require the adoption of cardiac mapping. Similarly, the article titled “Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports” in September 2020 stated there is an increase in morbidity and mortality in patients suffering from both cardiovascular complications and COVID-19. Therefore, more considerable attention is needed to viral infection-related heart damage during treatment. With such studies, the market is likely to increase as it provides the need for cardiac mapping due to the COVID-19 pandemic.
Cardiovascular diseases (CVDs) affect the heart and blood vessels of the body. These diseases affect one or more than one parts of the heart and blood vessels. Patients suffering from CVDs can be symptomatic or asymptomatic. According to the data published by the European Heart network in 2021 reported that in the European Union more than 60 million people live with Cardiovascular disease and close to 13 million new cases of cardiovascular diseases are diagnosed every year. Similarly, According to data from the Longitudinal Ageing Study of India (LASI) released by the Union Ministry of Family and Health Welfare on January 6, 2020, the self-reported prevalence of cardiovascular disease is rising with the age. The same source also reported that the self-reported prevalence of cardiovascular diseases among the adults aged 45-59 is 21.9%, people of age 60-74 is 33.8% and the age more than 75 years is 37.4%.
Factors such as product launches and approvals are key for the growth of the market in the upcoming future. In August 2020, Biosense Webster launched the latest Carto heart mapping system generation. The Carto Prime mapping module adds tools to the Carto 3 platform for further addressing all major complex arrhythmias, with improvements in mapping capabilities that help to reduce ablation times compared to standard mapping algorithms. With such launches, the market is likely to grow in the upcoming future. Product approvals are another factor in the growth of the market. In November 2020, Abbott received CE Mark and approval in Australia for its new EnSite X EP System, launching it throughout Europe and Australia. The EnSite X System is the only system that offers the option to navigate the cardiac anatomy in two different ways on one platform. The EnSite X System has advanced imaging capabilities that create a three-dimensional (3D) model of the patient’s cardiac anatomy in real-time, allowing physicians to see areas of the heart that need ablation treatment. With such approvals, the market is likely to grow in the future.
However, the lack of skilled electrophysiologists will likely hinder the market’s growth.
Cardiac Mapping Market Trends
Atrial Fibrillation Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Factors such as increasing atrial fibrillation, research studies, and initiatives are expected to drive the growth of the segment in the upcoming future. According to the Centers for Disease Control and Prevention(CDC), in 2020, more than 454,000 hospitalizations with AFib as the primary diagnosis happen each year in the United States. It is estimated that 12.1 million people in the United States will have atrial fibrillation (AFib) in 2030. Similarly, the article titled ‘ Epidemiology of Atrial Fibrillation in the 21st Century ‘ published in June 2020 mentioned that it was estimated that by 2050 Atrial Fibrillation would be diagnosed at least in 72 million individuals in Asia. Such increased incidence of Atrial fibrillation is expected to drive the growth of the studied segment during the forecast period.
Moreover, in June 2021, Cardiac Insights, Inc., a United States-based healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and diagnosis of cardiac arrhythmias, such as atrial fibrillation (Afib) announced launching its Cardea SOLO ECG System at Arab Health 2021, the largest healthcare exhibition in the Middle East. In August 2020, Boston Scientific developed the LUX-Dx implantable cardiac monitoring (ICM) system for the long-term diagnosis of arrhythmias associated with conditions such as atrial fibrillation and syncope. . It received clearance for commercialization in the US under the Class II medical device category in June 2020.
Hence, the abovementioned factors are expected to drive the growth of the studied segment during the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
The North American region is expected t hold a significant share in the growth of the market during the forecast period.
With the rising focus on patient care and need, supported by the well-developed infrastructure and technologically advanced healthcare system, the increasing burden of cardiac diseases and rising geriatric population is expected to drive the market growth in the region. According to the article titled ‘ Heart Disease and Stroke’ published in February 2022 As cardiac mapping devices are used for properly diagnosing and treating cardiac diseases, the prevalence of cardiac diseases is expected to boost the market’s growth.
Also, according to the Centres for Disease Control and Prevention (CDC), in September 2020. Every year, about 805,000 Americans have a heart attack. As the number of deaths due to heart diseases increases, there is a growing demand for the proper detection and diagnosis of cardiac diseases and mapping devices to fulfill the unmet needs. Hence are expected to show growth over the forecast period. According to the article titled ‘ Heart Disease in Canada’ published in July 2022, about 1 in 12 Canadians adults aged 20 and over live with diagnosed heart disease. This increased risk among the Canadian population is driving the market’s growth.
Also, the increasing product approvals for the Cardiac mapping in North American region is also expected to drive the growth of the market during the forecast period. For instance, in January 2022 Abbott recived the clearance from the Food and Drug Administrtaion (FDA) for the EnSITE X EP system with EnSite Omnipolar Technology, a cardiac mapping platform in United States.
Hence, the above mentioned factors are expected to drive the growth of the market in the studied region during the forecast period.
Cardiac Mapping Market Competitor Analysis
The market is partially fragmented and consists of several major players. Biosense Webster, Inc., Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, and Acutus Medical are currently dominating the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Target Diseases and Geriatric Population
4.2.2 Growing Investments, Funds, and Grants
4.3 Market Restraints
4.3.1 Lack of Skilled and Experienced Electrophysiologists
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Contact Cardiac Mapping Systems
5.1.2 Non-Contact Cardiac Mapping Systems
5.2 Indication
5.2.1 Atrial Fibrillation
5.2.2 Atrial Flutter
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Acutus Medical
6.1.3 Angiodynamics
6.1.4 APN Health, LLC
6.1.5 Biosense Webster, Inc.
6.1.6 Biosig Technologies, Inc.
6.1.7 Boston Scientific Corporation
6.1.8 Kardium, Inc.
6.1.9 Koninklijke Philips N.V.
6.1.10 Lepu Medical
6.1.11 Medtronic Plc
6.1.12 Microport Scientific Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS